Next Generation Gynecological Cancer Diagnostic Market Growth Analysis Report 2022-2028

Market Overview:
The Next Generation Gynecological Cancer Diagnostic Market is expected to grow at a significant growth rate, and the analysis period is 2022-2028, considering base year as 2021.
Gynecologic cancer is cancer that develops in a woman's reproductive organs. Cancer is always named after the body part in which it first manifests itself. Gynecologic cancers can develop in any part of a woman's pelvis, which is the area beneath the stomach and between the hip bones. Gynecologic cancers include cervical, ovarian, uterine, vaginal, and vulvar cancers. The most common gynecologic cancer is ovarian cancer. The development of innovative techniques for the diagnosis of gynecologic cancer, such as quantitative polymerase chain reaction (qPCR) & multiplexing, next-generation sequencing, lab-on-a-chip (LOAC) & reverse transcription-polymerase chain reaction (RT-PCR), and microarray, has resulted from technological advancement.

Read More:
https://introspectivemarketresearch.com/reports/next-generation-gynecological-cancer-diagnostic-market/

Market Dynamics:
Driver:
During the analysis period, the main factor stimulating the development of next-generation gynecological cancer diagnoses was an increase in the number of gynecological cancer cases. Breast cancer is the most common cancer diagnosed in women worldwide, while cervical cancer is the fourth most common cancer in women, with an estimated 604,000 new cases in 2020. In 2020, low- and middle-income countries will account for approximately 90% of the estimated 342,000 cervical cancer deaths. HIV-positive women are six times more likely to develop cervical cancer than HIV-negative women, with HIV accounting for approximately 5% of all cervical cancer cases. Furthermore, HIV causes a disproportionate amount of cervical cancer in young women worldwide.

Opportunities:
30 to 50% of cancers can be avoided by avoiding risk factors and implementing evidence-based prevention strategies. Cancer can be reduced by early detection, as well as adequate treatment and care for cancer patients. Many cancers can be cured if they are detected early and treated appropriately. Several governments have taken steps to combat noncommunicable disease spread. Cardiovascular disease, cancer, chronic respiratory disease, diabetes, and other noncommunicable diseases are thought to account for more than 60% of all deaths in India.

Request Sample Report:
https://introspectivemarketresearch.com/request/16267

Market Segmentation
Segmentation Analysis Of Next Generation Gynecological Cancer Diagnostic Market
By technology, the Next Generation Sequencing segment is anticipated to develop at the highest CAGR over the forecasted timeframe. Next-Generation Sequencing has proven to be a valuable tool for obtaining a deeper and more precise look into the molecular underpinnings of individual tumors. When compared to traditional approaches, NGS has the potential to have a significant impact on the field of oncology due to its accuracy, sensitivity, and speed. Since NGS can test numerous genes in a single assay, it eliminates the need for multiple tests to find the causative mutation thus, supporting the development of the segment.
• qPCR & Multiplexing
• Next-Generation Sequencing
• LOAC & RT-PCR
• Other

By function, the companion diagnostics segment is anticipated to dominate the next-generation gynecological cancer diagnostic market over the forecasted timeframe. Companion diagnostics assist healthcare professionals in determining a patient's response to a specific agent to improve cancer patient outcomes and improve personalized medicine. This also aids in the reduction of rising healthcare expenses by limiting drug use to only those who will significantly benefit from it thus, strengthening the expansion of the segment in the projected period.
• Companion Diagnostics
• Therapeutic & Monitoring
• Prognostic
• Cancer Screening
• Risk Analysis

By application, the biomarker development segment is expected to lead the development of the next-generation gynecological cancer diagnostic market. Patients with the same cancer type used to get the same treatment, but research has shown that tumors, even within the same cancer type, have distinct characteristics. Physicians are increasingly relying on cancer biomarkers to learn more about a patient's tumor and predict which treatment will be most effective against their specific cancer. Biomarkers can be utilized to personalize therapy for individual patients, reducing treatment costs.
• Biomarker Development
• CTC Analysis
• Proteomic Analysis
• Epigenetic Analysis
• Others

Regional Analysis Of Next Generation Gynecological Cancer Diagnostic Market
The North American region is anticipated to dominate the next-generation cancer diagnostics market over the forecasted period attributed to the growing prevalence of ovarian cancer. According to the American Cancer Society, about 19,880 women in the United States will receive a new diagnosis of ovarian cancer in 2022. The Society also estimated that 12,810 women will die from ovarian cancer.

The European region is expected to have the second-highest share of the next-generation cancer diagnostics market in the analysis period. Cervical cancer is predicted to account for 2.5 % of cancer cases (excluding non-melanoma skin cancers) identified in women in 2020, and 2.4 % of all cancer deaths in women. Cervical cancer is the 11th most common cancer in women and the 12th most common cause of cancer death in them.

The next-generation cancer diagnostics market in the Asia-Pacific region is anticipated to develop at the highest CAGR over the analysis period. According to ICO/IARC Information Centre on HPV and Cancer, every year 123,907 women in India are diagnosed with cervical cancer, and 77,348 die from the disease. Cervical cancer is the second most common disease among women in India, and the second most common cancer among women aged 15 to 44.
• North America (U.S., Canada, Mexico)
• Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
• Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
• Middle East & Africa (Turkey, Saudi Arabia, Iran, UAE, Africa, Rest of MEA)
• South America (Brazil, Argentina, Rest of SA)

Top Key Players Covered In Next Generation Gynecological Cancer Diagnostic Market
• Agilent Technologies (California, United States)
• ARUP Laboratories (California, United States)
• BGI Genomics (Shenzhen, China)
• CENTOGENE N.V. (Rostock, Germany)
• F. Hoffmann-La Roche Ltd (Basel, Switzerland)
• Fulgent Genetics (California, United States)
• Illumina Inc. (California, United States)
• Invitae Corporation (California, United States)
• Konica Minolta Inc. (Tokyo, Japan)
• Laboratory Corporation of America Holdings (California, United States)
• Myriad Genetics (Utah, United States)
• OPKO Health Inc. (Florida, United States)
• QIAGEN N.V. (Germany)
• Quest Diagnostics Incorporated (US)
• Thermo Fisher Scientific Inc. (US) and Other Major Players.

Key Industry Developments In The Next Generation Gynecological Cancer Diagnostic Market
In May 2022, Agilent Technologies Inc. announced that their PD-L1 IHC 22C3 pharmDx, Code SK006, has received EU CE-IVD approval for use in cervical cancer. PD-L1 IHC 22C3 pharmDx can help identify cervical cancer patients who may benefit from treatment with KEYTRUDA® (pembrolizumab).

In February 2021, QIAGEN and INOVIO Pharmaceuticals have announced a new master collaboration agreement to develop liquid biopsy-based companion* diagnostic solutions based on next-generation sequencing (NGS) technology to complement INOVIO's therapies.
In July 2020, Thermo Fisher Scientific signed a CDx agreement with Chugai Pharmaceutical and has applied to the Ministry of Health, Labor, and Welfare (MHLW) to expand the use of the Oncomine Dx Target Test in Japan.

Inquire Before Buying:
https://introspectivemarketresearch.com/request/16267

Table Of Content
Chapter 1: Introduction
 1.1 Research Objectives
 1.2 Research Methodology
 1.3 Research Process
 1.4 Scope and Coverage
  1.4.1 Market Definition
  1.4.2 Key Questions Answered
 1.5 Market Segmentation

Chapter 2:Executive Summary

Chapter 3:Growth Opportunities By Segment
 3.1 By Technology
 3.2 By Function
 3.3 By Application

Chapter 4: Market Landscape
 4.1 Porter's Five Forces Analysis
  4.1.1 Bargaining Power of Supplier
  4.1.2 Threat of New Entrants
  4.1.3 Threat of Substitutes
  4.1.4 Competitive Rivalry
  4.1.5 Bargaining Power Among Buyers
 4.2 Industry Value Chain Analysis
 4.3 Market Dynamics
  4.3.1 Drivers
  4.3.2 Restraints
  4.3.3 Opportunities
  4.5.4 Challenges
 4.4 Pestle Analysis
 4.5 Technological Roadmap
 4.6 Regulatory Landscape
 4.7 SWOT Analysis
 4.8 Price Trend Analysis
 4.9 Patent Analysis
 4.10 Analysis of the Impact of Covid-19
  4.10.1 Impact on the Overall Market
  4.10.2 Impact on the Supply Chain
  4.10.3 Impact on the Key Manufacturers
  4.10.4 Impact on the Pricing
To Be Continue.

Buy This Report@
https://introspectivemarketresearch.com/checkout/?user=1&_sid=16267

Related Reports:
https://introspectivemarketresearch.com/reports/non-small-cell-lung-cancer-market/
https://introspectivemarketresearch.com/reports/cancer-tissue-diagnostics-market/

Contact us:
Introspective Market Research
3001 S King Drive,
Chicago, Illionis
60616 USA
Ph no: +1-773-382-1047
Email: sales@introspectivemarketresearch.com

About Us:
Introspective Market Research (introspectivemarketresearch.com) is a visionary research consulting firm dedicated to assist our clients grow and have a successful impact on the market. Our team at IMR is ready to assist our clients flourish their business by offering strategies to gain success and monopoly in their respective fields. We are a global market research company, specialized in using big data and advanced analytics to show the bigger picture of the market trends. We help our clients to think differently and build better tomorrow for all of us. We are a technology-driven research company, we analyse extremely large sets of data to discover deeper insights and provide conclusive

This release was published on openPR.